HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Accepted manuscript (PDF) All Versions of this Article: ERC-08-0244v1 16/2/333    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Lanari, C. Articles by Molinolo, A. Search for Related Content PubMed PubMed Citation Articles by Lanari, C. Articles by Molinolo, A.

C Lanari, Laboratorio de Carcinogenesis Hormonal, Instituto de Biologia y Medicina Experimental, Buenos Aires, Argentina
C Lamb, Laboratorio de Carcinogenesis Hormonal, Instituto de Biologia y Medicina Experimental, Buenos Aires, Argentina
V Fabris, Laboratorio de Carcinogenesis Hormonal, Instituto de Biologia y Medicina Experimental, Buenos Aires, Argentina
L Helguero, Department of Biosciences and Nutrition, Karolinska Institutet, Novum, Sweden
R Soldati, Laboratorio de Carcinogenesis Hormonal, Instituto de Biologia y Medicina Experimental, Buenos Aires, Argentina
M Bottino, Laboratorio de Carcinogenesis Hormonal, Instituto de Biologia y Medicina Experimental, Buenos Aires, Argentina
S Giulianelli, Laboratorio de Carcinogenesis Hormonal, Instituto de Biologia y Medicina Experimental, Buenos Aires, Argentina
J Cerliani, Laboratorio de Carcinogenesis Hormonal, Instituto de Biologia y Medicina Experimental, Buenos Aires, Argentina
V Wargon, Laboratorio de Carcinogenesis Hormonal, Instituto de Biologia y Medicina Experimental, Buenos Aires, Argentina
A Molinolo, Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, Bethesda, United States

Correspondence: Claudia Lanari, Email: clanari{at}dna.uba.ar

Abstract

More than 60% of all breast neoplasias are ductal carcinomas expressing estrogen (ER) and progesterone receptors (PR). In contrast, most of the spontaneous, chemically or MMTV induced tumors, as well as tumors arising in genetically modified mice do not express hormone receptors. We developed a model of breast cancer in which the administration of medroxyprogesterone acetate (MPA) to BALB/c female mice induces mammary ductal carcinomas with a mean latency of 52 weeks and an incidence of about 80%. These tumors are hormone-dependent, metastatic, express both ER and PR, and are maintained by syngeneic transplants. The model has been further refined to include mammary carcinomas that evolve through different stages of hormone dependency, as well as several hormone-responsive cell lines. In this review, we describe the main features of this tumor model, highlighting the role of PR as a trigger of key signaling pathways mediating tumor growth. In addition, we discussthe relevance of this model in comparison with other currently used breast cancer models pointing out its advantages and limitations and how, this model may be suitable to unravel key questions in breast cancer.